One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Veterinary Vaccine Adjuvants Market

[ 英語タイトル ] Veterinary Vaccine Adjuvants Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083117
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 114
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Bioveta AS
- Brenntag Biosector AS
- Novavax
- Phibro Animal Health Corporation
- SPI Pharma
- Zoetis

[Report Description]

The veterinary vaccine adjuvant market is anticipated to register a CAGR of around 6.4%, during the forecast period. The growth of this market is owing to several factors, such as the rising use of adjuvants in the vaccine, increasing livestock population and their associated diseases, and the high incidence of infectious zoonotic diseases. As per the Centers for Disease Control and Prevention (CDC), zoonotic diseases are very common and about three out of every four new or emerging infectious diseases in people are spread from animals, and more than six out of every 10 known infectious diseases in people are spread from animals. So, for the treatment of the aforementioned infectious zoonotic diseases, various types of vaccines are used. Thus, the growing burden of zoonotic diseases is among the major growth factor for the veterinary vaccine adjuvant market.

Key Market Trends

The Alum and Calcium Salts Segment is Expected to Hold the Largest Share in the Market

Aluminum-based adjuvants have been used most commonly for vaccine preparations for more than 80 years. They include aluminum hydroxide and phosphate adjuvants, as well as calcium phosphate adjuvants. In addition, the safety of these adjuvants is excellent, and there are very few side effects. However, there are some allergic reactions and granulomas occasionally in a few cases. Moreover, recent developments, such as the use of aluminum oxyhydroxide nanoparticles in the formulation of vaccine adjuvants, are more effective in the prevention of infectious diseases and the treatment of various diseases. Furthermore, the increasing funding and investments for developing and producing new vaccines are boosting the segment.

North America is Expected to Exhibit Major Contribution Over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. This is due to the rising adoption of companion animals, increasing pet healthcare insurance, and improved veterinary healthcare infrastructure. In the North American region, the United States holds the largest market share. Additionally, with the rising trends of zoonotic diseases in the United States, the associated use of veterinary vaccines is also increasing. Hence, it is expected to propel the growth of the veterinary vaccine adjuvants market over the forecast period.

Competitive Landscape

The veterinary vaccine adjuvant market is moderately competitive and consists of several major players. In terms of market share, some of the major players currently dominate the market. With the rising prevalence of infectious diseases in the animals, few other smaller players are expected to enter the market in the coming years. Some of the major players of the market are SEPPIC, SPI Pharma, Brenntag Biosector AS, Bioveta AS, and Zoetis, among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Use of Adjuvants in Vaccine
4.2.2 Increase in Livestock Population and their Associated Diseases
4.2.3 High Incidence of Infectious Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Toxicity and Side Effects of Adjuvants
4.3.2 Stringent Regulatory Environment and Time-consuming Approvals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Alum and Calcium Salts
5.1.2 Oil Emulsion Adjuvants
5.1.3 Liposomes and Archaeosomes
5.1.4 Nanoparticles and Microparticles
5.1.5 Other Types
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Subcutaneous
5.2.3 Intramuscular
5.2.4 Other Routes of Administration
5.3 By Animal Type
5.3.1 Livestock
5.3.2 Companion Animal
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bioveta AS
6.1.2 Brenntag Biosector AS
6.1.3 Novavax
6.1.4 Phibro Animal Health Corporation
6.1.5 SEPPIC
6.1.6 SPI Pharma
6.1.7 Zoetis




Recommended reports